Tempus AI (NASDAQ:TEM) Reaches New 1-Year High – Time to Buy?

Shares of Tempus AI, Inc. (NASDAQ:TEM) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $80.70 and last traded at $80.24, with a volume of 7026374 shares trading hands. The stock had previously closed at $73.88.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. William Blair cut shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, TD Cowen reaffirmed a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Price Performance

The firm’s 50-day moving average is $46.60 and its two-hundred day moving average is $50.29. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Buying and Selling at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the sale, the insider now directly owns 15,218,365 shares in the company, valued at $534,164,611.50. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jennifer A. Doudna sold 1,320 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the transaction, the director now directly owns 36,011 shares in the company, valued at approximately $3,240,990. This represents a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,401,779 shares of company stock valued at $115,707,361 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Comerica Bank grew its stake in shares of Tempus AI by 342.5% in the 4th quarter. Comerica Bank now owns 112,145 shares of the company’s stock valued at $3,786,000 after buying an additional 86,800 shares during the period. Tudor Investment Corp ET AL purchased a new position in Tempus AI in the fourth quarter worth approximately $348,000. Mission Creek Capital Partners Inc. acquired a new stake in Tempus AI during the fourth quarter worth $1,612,000. Oxford Asset Management LLP acquired a new stake in Tempus AI during the fourth quarter worth $457,000. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in Tempus AI in the fourth quarter valued at $775,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.